Abstract
Aim: This research aims to investigate the therapeutic effect of shRNA injected into the tail vein on Parkinson’s disease in mice based on SNCA gene mutation of α-synuclein and explore the migration mechanism of α-synuclein. Methods: SCNA +/+ mice are used to induce α-synuclein by tuberculin pff and then establish the model of Parkinson’s disease in mice. Besides, AAV-shRNA is used to set the control group and the experimental group at different times. Open-field test, tail suspension test, and immunofluorescence are adopted to explore the therapeutic effect of shRNA and the migration mechanism of α-synuclein. Results: shRNA inhibits P-α-syn in the brain of mice afflicted with Parkinson’s disease, which has obvious behavioral therapy. The whole brain invasion of α-synuclein in OB of the olfactory bulb occurs, while the invasion of α-synuclein in CPu of the dorsal striatum only exists in the downstream brain region. Conclusion: Intravenous injection of shRNA into the tail vein can effectively inhibit α-synuclein with symptomatic therapeutic effect on mice with Parkinson’s disease, and the earlier injection enables better therapeutic effect.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Transactions on Materials, Biotechnology and Life Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
